700 Veterans Circle
About Arbutus Biopharma
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company’s current focus areas include Hepatitis B virus (HBV) and coronaviruses. In HBV, Arbutus is developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that they intend to combine to improve the outcomes of patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. Arbutus’ lead compound, AB-729 is the only RNAi therapeutic with evidence of immune re-awakening and is currently being evaluated in multiple phase 2 clinical trials. Arbutus has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including COVID-19). Arbutus is also exploring oncology applications for its internal PD-L1 portfolio.
Company Ownership: Public
Stock Symbol: ABUS
Stock Exchange: NASDAQ
413 articles with Arbutus Biopharma
Arbutus Biopharma Corporation announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 11:30 am ET in Miami, FL.
Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in its COVID-19 vaccine.
Arbutus Biopharma Corporation today reports its first quarter 2022 financial results and provides pipeline updates.
Arbutus Biopharma Corporation today announced that it has scheduled its first quarter 2022 financial results and corporate update for Thursday, May 5, 2022.
Who is to thank for the COVID vaccine? Many major biopharma companies are asking that question after a series of lawsuits over patent rights to the vaccine and its associated technology.
Arbutus Biopharma Corporation today reports its fourth quarter and year end 2021 financial results and provides pipeline updates.
On Monday, Arbutus and Genevant filed a lawsuit against Moderna challenging patent infringement.
Arbutus Biopharma Corporation and Genevant Sciences today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc.
Arbutus Biopharma Corporation today announced that it has scheduled its fourth quarter and year end 2021 financial results and corporate update for Thursday, March 3, 2022.
Arbutus Biopharma Corporation today announced its 2022 corporate objectives and provided a financial update.
Arbutus Biopharma Corporation announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10 - 13, 2022.
Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection
Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection.
Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan
Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan.
Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement
Arbutus Biopharma Corporation announced today that Arbutus Biopharma has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks.
The U.S. Centers for Disease Control and Prevention (CDC) reported that the Omicron variant of COVID-19 had been identified in California.
Arbutus Biopharma Corporation today announced that Tram Tran, M.D. has been appointed to the Arbutus Board of Directors
Arbutus Biopharma Corporation today announced that the Company will participate in a virtual fireside chat at the Jefferies London Healthcare Conference.
Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®
Arbutus Biopharma Corporation today announced new AB-729 safety and efficacy data, as well as long-term data from HBV patients following discontinuation of treatment with AB-729. .
Arbutus Biopharma Corporation today reports its third quarter 2021 financial results and provides a corporate update.
Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021
Arbutus Biopharma Corporation announced that the Company will be presenting data on the effects of its GalNAc-siRNA, AB-729, in chronic hepatitis B patients on nucleoside analogue therapy at The American Association for the Study of Liver Diseases – The Liver Meeting® 2021 – The Digital Experience™, taking place from November 12-15, 2021.